SG11202105795XA - Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 - Google Patents

Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1

Info

Publication number
SG11202105795XA
SG11202105795XA SG11202105795XA SG11202105795XA SG11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA SG 11202105795X A SG11202105795X A SG 11202105795XA
Authority
SG
Singapore
Prior art keywords
hsd1
estra
inhibitors
pyrazole ring
compounds condensed
Prior art date
Application number
SG11202105795XA
Other languages
English (en)
Inventor
Leena Hirvelä
Marjo Hakola
Tero Linnanen
Pasi Koskimies
Camilla Stjernschantz
Original Assignee
Forendo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forendo Pharma Ltd filed Critical Forendo Pharma Ltd
Publication of SG11202105795XA publication Critical patent/SG11202105795XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0057Nitrogen and oxygen
    • C07J71/0068Nitrogen and oxygen at position 16(17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0042Nitrogen only
    • C07J71/0052Nitrogen only at position 16(17)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11202105795XA 2018-12-05 2019-12-05 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 SG11202105795XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20186056 2018-12-05
PCT/FI2019/050874 WO2020115371A1 (fr) 2018-12-05 2019-12-05 Composés estra-1,3,5(10)-triène condensés en position 16(17) avec un cycle pyrazole utilisés comme inhibiteurs de la 17-hsd1

Publications (1)

Publication Number Publication Date
SG11202105795XA true SG11202105795XA (en) 2021-06-29

Family

ID=69005734

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105795XA SG11202105795XA (en) 2018-12-05 2019-12-05 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1

Country Status (15)

Country Link
US (1) US20220041647A1 (fr)
EP (1) EP3891167B1 (fr)
JP (1) JP7417608B2 (fr)
KR (1) KR20210114390A (fr)
CN (1) CN113412269A (fr)
AU (2) AU2019393005B2 (fr)
BR (1) BR112021010598A2 (fr)
CA (1) CA3122049C (fr)
CL (1) CL2021001468A1 (fr)
EA (1) EA202191531A1 (fr)
IL (1) IL283588A (fr)
MX (1) MX2021006452A (fr)
SG (1) SG11202105795XA (fr)
UA (1) UA126881C2 (fr)
WO (1) WO2020115371A1 (fr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323089A1 (fr) 1998-03-11 1999-09-16 Endorecherche, Inc. Inhibiteurs de la 17.beta.-hydroxysteroide deshydrogenase du type 5 et du type 3 et methodes d'utilisation associees
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
DK1423381T3 (da) 2001-09-06 2007-05-07 Schering Corp 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
ATE471315T1 (de) 2001-10-17 2010-07-15 Schering Corp Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
EP1562901B1 (fr) 2002-11-18 2010-06-02 Schering Corporation Inhibiteurs de la 17beta-hydroxysteroide deshydrogenase de type 3 utilises pour le traitement de maladies androgeno-dependantes
JP4585320B2 (ja) 2002-12-17 2010-11-24 シェーリング コーポレイション 男性ホルモン依存性疾患の処置のための17β−ヒドロキシステロイドデヒドロゲナーゼ3型インヒビター
US7015211B2 (en) 2003-03-21 2006-03-21 Yale University 15α-substituted estradiol carboxylic acid esters as locally active estrogens
GB0306718D0 (en) 2003-03-24 2003-04-30 Sterix Ltd Compound
US20040224935A1 (en) 2003-04-07 2004-11-11 Endorecherche, Inc. Topical antiandrogenic steroids
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
DE102004032673A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1
DE102004032674A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
CA2609726C (fr) 2005-05-26 2013-10-01 Solvay Pharmaceuticals Gmbh Inhibiteurs de 17.beta.-hsd1 et sts
JP5268917B2 (ja) 2006-09-19 2013-08-21 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療学的に有効なトリアゾール類及びそれらの使用
MX2009005201A (es) 2006-11-30 2009-05-27 Solvay Pharm Gmbh Derivados de estratrieno sustituidos como inhibidores de 17beta hsd.
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US9024093B2 (en) 2008-11-20 2015-05-05 President And Fellows Of Harvard College Fluorination of organic compounds
AR096728A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
EP3013846B1 (fr) * 2013-06-25 2017-08-09 Forendo Pharma Ltd Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド 17β−ヒドロキシステロイドデヒドロゲナーゼ タイプ1の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
NZ760155A (en) * 2017-06-08 2022-09-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5

Also Published As

Publication number Publication date
CA3122049C (fr) 2023-10-17
KR20210114390A (ko) 2021-09-23
JP2022510386A (ja) 2022-01-26
CA3122049A1 (fr) 2020-06-11
UA126881C2 (uk) 2023-02-15
EP3891167A1 (fr) 2021-10-13
US20220041647A1 (en) 2022-02-10
EP3891167B1 (fr) 2024-11-13
AU2019393005B2 (en) 2022-12-15
EA202191531A1 (ru) 2021-09-03
IL283588A (en) 2021-07-29
WO2020115371A1 (fr) 2020-06-11
JP7417608B2 (ja) 2024-01-18
CL2021001468A1 (es) 2022-01-28
BR112021010598A2 (pt) 2021-08-24
AU2019393005A1 (en) 2021-07-29
CN113412269A (zh) 2021-09-17
MX2021006452A (es) 2021-09-28
AU2022279473A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
IL282468A (en) 2-Amino-n-heteroaryl-nicotinamides as inhibitors of nav1.8
IL289290A (en) Substituted benzyltriazole compounds for cbl-b inhibition, and other uses thereof
CA187130S (en) Vaporizer
CA185291S (en) Vaporizer
CA186350S (en) Vaporizer
HUE054690T2 (hu) 8-Oxetán-3-il-3,8-diazabiciklo[3.2.1]oktán-3-il-csoporttal szubsztituált vegyületek HIV inhibitorokként
GB2573892B (en) Low portland silica-lime cements
MX2016008851A (es) Compuesto esteroideo para su uso en el tratamiento de encefalopatia hepatica.
ZA201706520B (en) An adjuvant for a cement or a refractory concrete composition, the uses thereof, and cement and refractory concrete compositions
SG11202103356UA (en) Process for preparing short-chain olefins in the gas phase
GB2564129B (en) Self-compacting concrete composition
CA185281S (en) Vaporizer
SG11202005889WA (en) Process for the preparation of methyl mercaptan
PL3738452T3 (pl) Waporyzator
IL283588A (en) Compounds 1, 3, 5(10)-triane condensed at position 16(17) with a pyrazole ring as 17-hsd1 inhibitors
RS65529B1 (sr) 17-oksimi 15.beta.-[3-propanamido]-supstituisanih estra-1,3,5(10)-trien-17-ona za upotrebu u inhibiciji 17.beta.-hidroksisteroid dehidrogenaza
HUE054691T2 (hu) Eljárás 3,7-bisz(dimetilamino)fenotiazin-5-ílium-jodid elõállítására
IL277876A (en) A preparation for the treatment of one or more estrogen-related diseases
CA187806S (en) Vaporizer
EP3845528C0 (fr) Composés de pyrazole, compositions pharmaceutiques correspondantes et utilisation associées en tant qu'inhibiteurs de irak4
SG10201807686QA (en) An Article For Enriching Soil Fertility
CA192159S (en) Vaporizer
ZA202204152B (en) A solubilizing composition
CA185971S (en) Vaporizer
CA195113S (en) Vaporizer